Correlation of c-erbB-2 oncogene and p53 tumor suppressor gene with malignant transformation of hydatidiform mole

Journal of Obstetrics and Gynaecology Research

Volumn 32, Issue 3, 2006, Pages 265-272

  Yazaki Sun, Sue ^b   Daher, Silvia ^a,b   De Souza Ishigai, Márcia Marcelino ^b   Alves, Maria Teresa Seixas ^b   Mantovani, Teresa Meire ^b   Mattar, Rosiane ^b  

^a Paulista Medical School ^*  (Brazil)

^b FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

c erbB 2; Complete hydatidiform mole; Gestational trophoblast tumor; Oncogene; p53

Indexed keywords

CHORIONIC GONADOTROPIN BETA SUBUNIT; PROTEIN P53;

ADOLESCENT; ADULT; ARTICLE; CANCER REGRESSION; CELL NUCLEUS; CLINICAL ARTICLE; FEMALE; FOLLOW UP; GENE EXPRESSION; HUMAN; HYDATIDIFORM MOLE; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; ONCOGENE C ERB; TROPHOBLASTIC TUMOR; TUMOR GROWTH; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADULT; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; GENES, ERBB-2; GENES, P53; HUMANS; HYDATIDIFORM MOLE; MIDDLE AGED; PREGNANCY;

EID: 33744482308     PISSN: 13418076     EISSN: 14470756     Source Type: Journal    
DOI: 10.1111/j.1447-0756.2006.00397.x     Document Type: Article

References (30)

1. Greene FL, Page DL, Fleming ID. Gestational trophoblastic tumors. In : Greene FL, Page DL, Fleming ID (eds). AJCC Cancer Staging Handbook, 6th edn. New York : Springer, 2002 323 328.
2. Li MC, Hertz R, Spencer DB. Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma. Proc Soc Exp Biol Med 1956 93 : 361 366.
3. Hancock MD, Tidy MD. Current management of molar pregnancy. J Reprod Med 2002 47 : 347 354.
4. Slamon DJ. Proto-oncogenes and human cancers. N Engl J Med 1987 317 : 955 957.
5. Kay EW, Barry-Walsh CJ, Cassidy M, Curran B, Leader M. C-erbB-2 immunostaining: Problems with interpretation. J Clin Pathol 1994 47 : 816 822.
6. Yang X, Zhang Z, Jia C, Li J, Yin L, Jiang S. The relationship between expression of c-ras, c-erbB-2, nm23, and p53 gene products and development of trophoblastic tumor and their predictive significance for the malignant transformation of complete hydatidiform mole. Gynecol Oncol 2002 85 : 438 444.
7. Bauer M, Horn LC, Kowalzik J, Mair W, Czerwenka K. C-erbB-2 amplification and expression in gestational trophoblastic disease correlates with DNA content and karyotype. Gen Diag Pathol 1997 143 : 185 190.
8. Jelincic D, Hudelist G, Singer CF et al. Clinicopathologic profile of gestational trophoblastic disease. Wien Klin Woch 2003 115 : 29 35.
9. Fulop V, Mok SC, Genest DR, Szigetvari I, Cseh I, Berkowitz RS. c-myc, c-erbB-2, c-fms and bcl-2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma. J Reprod Med 1998 43 : 101 110.
10. Lane DP. P53, guardian of the genome. Nature 1992 358 : 15 16.
11. Nigro JM, Baker SJ, Preisinger AC et al. Mutations in the p53 gene occur in diverse human tumour types. Nature 1989 342 : 705 708.
12. Fulop V, Mok CS, Genest DR, Gati I, Doszpod J, Berkowitz R. p53, p21, Rb and mdm2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma. J Reprod Med 1998 43 : 119 127.
13. Lee YS. p53 expression in gestational trophoblastic disease. Int J Gynecol Pathol 1995 14 : 119 124.
14. Kale A, Söylemez F, Ensari A. Expressions of proliferation markers (Ki-67, proliferating cell nuclear antigen, and silver-staining nucleolar organizer regions) and of p53 tumor protein in gestational trophoblastic disease. Am J Obstet Gynecol 2001 184 : 567 574.
15. Al-Bozom IA. p53 and Bcl-2 oncoprotein expression in placentas with hydropic changes and partial and complete moles. APMIS 2000 108 : 756 760.
16. Schammel DP, Bocklage T. p53 PCNA, and Ki-67 in hydropic molar and nonmolar placentas: an immunohistochemical study. Int J Gynecol Pathol 1996 15 : 158 166.
17. Cheville JC, Robinson RA, Benda JA. p53 expression in placentas with hydropic change and hydatidiform moles. Mod Pathol 1996 4 : 392 396.
18. Cheung ANY, Shen DH, Khoo US et al. Immunohistochemical and mutational analysis of p53 tumor suppressor gene in gestational trophoblastic disease: correlation with mdm2, proliferation index, and clinicopathologic parameters. Int J Gynecol Cancer 1999 9 : 123 130.
19. Chen CA, Chen YH, Chen TM et al. Infrequent mutation in tumor suppressor gene p53 in gestational trophoblastic neoplasia. Carcinogenesis 1994 15 : 2221 2223.
20. Cheung ANY, Srivastava G, Chung LP et al. Expression of the p53 gene in trophoblastic cells in hydatidiform moles and normal human placentas. J Reprod Med 1994 39 : 223 227.
21. Shi XF, Xie X, Zhao CL et al. Lack of mutation in tumour-supressor gene p53 in gestational trophoblastic tumours. Br J Cancer 1996 73 : 1216 1219.
22. Halperin R, Peller S, Sandbank J, Bukovsky I, Schneider D. Expression of the p53 gene and apoptosis in gestational trophoblastic disease. Placenta 2000 21 : 58 62.
23. Szulman AE, Surti U. The syndromes of hydatidiform mole. II. Morphologic evolution of the complete and partial mole. Am J Obstet Gynecol 1978 132 : 20 27.
24. Cameron B, Gown AM, Tamimi HK. Expression of c-erb B-2 oncogene product in persistent gestational trophoblastic disease. Am J Obstet Gynecol 1994 170 : 1616 1622.
25. Rhodes A, Bharat J, Anderson E, Dodson AR, Balaton AJ. Evaluation of HER-2/neu immunohistochemical assay sensitivity and scoring on formalin-fixed and paraffin-processed cell lines and breast tumors. A comparative study involving results from laboratories in 21 countries. Am J Clin Pathol 2002 118 : 408 417.
26. Wang DP, Fujii S, Konishi I et al. Expression of c-erbB-2 protein and epidermal growth factor receptor in normal tissues of the female genital tract and in the placenta. Virchows Arch A Pathol Anat Histopathol 1992 420 : 385 393.
27. Zhang H, Richter M, Greene MI. Therapeutic monoclonal antibodies for the ErbB family of receptor tyrosine kinases. Cancer Biol Ther 2003 2 4 Suppl 1 S122 S126.
28. Spigel DR, Burstein HJ. Trastuzumab regimens for HER2-overexpressing metastatic breast cancer. Clin Breast Cancer 2003 4 : 329 337.
29. Kauraniemi P, Hautaniemi S, Autio R et al. Effects of Herceptin treatment on global gene expression patterns in HER2-amplified and nonamplified breast cancer cell lines. Oncogene 2004 23 : 1010 1013.
30. Toi M, Takada M, Bando H et al. Current status of antibody therapy for breast cancer. Breast Cancer 2004 11 : 10.